Literature DB >> 25119743

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?

Marco Aurélio P Sáfadi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25119743      PMCID： PMC4183015          DOI： 10.1590/0103-05822014322

Source DB:  PubMed          Journal:  Rev Paul Pediatr        ISSN： 0103-0582


× No keyword cloud information.
  13 in total

1.  Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.

Authors:  Maarten O Blanken; Maroeska M Rovers; Jorine M Molenaar; Pauline L Winkler-Seinstra; Adam Meijer; Jan L L Kimpen; Louis Bont
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

2.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

Authors:  J Chin; R L Magoffin; L A Shearer; J H Schieble; E H Lennette
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

3.  Respiratory infections in children up to two years of age on prophylaxis with palivizumab.

Authors:  Ana Isabel M P Monteiro; Nancy Cristina J Bellei; Alessandra Ramos Sousa; Amélia Miyashiro N dos Santos; Lily Yin Weckx
Journal:  Rev Paul Pediatr       Date:  2014-06

4.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

5.  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.

Authors:  R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

6.  Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.

Authors:  Hong Zhou; William W Thompson; Cecile G Viboud; Corinne M Ringholz; Po-Yung Cheng; Claudia Steiner; Glen R Abedi; Larry J Anderson; Lynnette Brammer; David K Shay
Journal:  Clin Infect Dis       Date:  2012-04-10       Impact factor: 9.079

7.  Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.

Authors:  Nele Sigurs; Per M Gustafsson; Ragnar Bjarnason; Fredrik Lundberg; Susanne Schmidt; Fridrik Sigurbergsson; Bengt Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2004-10-29       Impact factor: 21.405

8.  Trends in bronchiolitis hospitalizations in the United States, 2000-2009.

Authors:  Kohei Hasegawa; Yusuke Tsugawa; David F M Brown; Jonathan M Mansbach; Carlos A Camargo
Journal:  Pediatrics       Date:  2013-06-03       Impact factor: 7.124

9.  The burden of respiratory syncytial virus infection in young children.

Authors:  Caroline Breese Hall; Geoffrey A Weinberg; Marika K Iwane; Aaron K Blumkin; Kathryn M Edwards; Mary A Staat; Peggy Auinger; Marie R Griffin; Katherine A Poehling; Dean Erdman; Carlos G Grijalva; Yuwei Zhu; Peter Szilagyi
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

10.  Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.

Authors:  Bosco Paes; Ian Mitchell; Abby Li; Tetsuhiro Harimoto; Krista L Lanctôt
Journal:  Clin Dev Immunol       Date:  2013-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.